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 28 
Synopsis 29 
Drawing on a Cochrane systematic review this paper examines the relatively limited range of outcomes 30 
measured in published evaluations of antimicrobial stewardship interventions (ASI) in hospitals. We 31 
describe a structured framework for considering the range of consequences that ASI can have, in terms 32 
of their desirability and the extent to which they were expected when planning an ASI: expected, 33 
desirable consequences (intervention goals); expected, undesirable consequences (intervention trade-34 
offs); unexpected, undesirable consequences (unpleasant surprises); and unexpected, desirable 35 
consequences (pleasant surprises). Of 49 randomised controlled trials (RCTs) identified by the Cochrane 36 
review, 28 (57%) pre-specified increased length of stay and/or mortality as potential trade-offs of ASI, 37 
with measurement intended to provide reassurance about safety. In actuality, some studies found 38 
unexpected decreases in length of stay (a pleasant surprise). In contrast, only 11 (10%) of 110 39 
interrupted time series (ITS) studies included any information about unintended consequences, with 10 40 
examining unexpected, undesirable outcomes (unpleasant surprises) using case-control, qualitative or 41 
cohort designs. Overall, a large proportion of the ASI reported in the literature only assess impact on 42 
their targeted process goals – antimicrobial prescribing – with limited examination of other potential 43 
outcomes including microbial and clinical outcomes. Achieving a balanced accounting of the impact of 44 
an ASI requires careful consideration of expected undesirable effects (potential trade-offs) from the 45 
outset, and more consideration of unexpected effects after implementation (both pleasant and 46 
unpleasant surprises, although the latter will often be more important). The proposed framework 47 
supports the systematic consideration of all types of consequences of improvement before and after 48 
implementation.  49 
 50 
 51 
 52 
 53 
 54 
 55 
 56 
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Introduction 57 
Increasing antimicrobial resistance poses a major threat to human health. Health services internationally 58 
have responded by planning or implementing a range of antimicrobial stewardship interventions (ASI) to 59 
promote judicious use of antimicrobials to preserve their future effectiveness.1 ASI are usually complex 60 
with multiple components,2 with expected benefits balanced against unintended adverse consequences 61 
such as delayed or ineffective treatment of life threatening infections.3-5 Antimicrobial stewardship 62 
shares many characteristics with other healthcare quality improvement programmes, including that 63 
improvers typically focus on delivering a pre-defined set of benefits in terms of processes of care. 64 
However, any evaluation of the impact of an improvement programme should report all unintended 65 
consequences (which may be negative or positive), as well as the targeted processes of care that are 66 
intended to improve.6 In this paper, we examine the range of outcomes measured in published 67 
evaluations of ASI in hospitals, and describe a framework for thinking about the consequences of 68 
interventions to help achieve a balanced accounting of impact.  69 
 70 
What outcomes do ASI measure?  71 
The recently updated Cochrane systematic review of the impact of ASI in hospital5 included 221 studies 72 
in total, with 49 randomised controlled trials (RCTs) and 110 interrupted time series (ITS) studies 73 
contributing to at least one meta-regression or meta-analysis. Reflecting the design of the Cochrane 74 
review, all the included RCTs and ITS studies measured antimicrobial outcomes, with 46 RCTs (93.8%) 75 
and 101 ITSs (91.8%) aiming to improve antimicrobial treatment and the remaining three RCTs (6.1%) 76 
and nine ITS studies (8.2%) aiming to improve surgical prophylaxis (Table 1). 77 
 78 
In contrast, only a minority of studies examined any other type of outcomes. Only five RCTs (10.2%) and 79 
26 ITSs (23.6%) examined microbial outcomes, most commonly colonisation or infection with resistant 80 
bacteria, or Clostridium difficile infection (CDI), with an explicit or implicit assumption that these would 81 
reduce. 28 (57.1%) RCTs and four (3.6%) ITSs examined all-cause mortality while length of hospital stay 82 
was measured in 15 RCTs (30.6%) and two ITSs (1.8%). However, it was often unclear whether length of 83 
stay and mortality were expected to change, and if so, in which direction (whether there was a hope 84 
that the ASI would reduce mortality and length of stay, or a fear that they would increase). 85 
 86 
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Other outcomes relating to the impact and safety of interventions were reported in 23 RCTs (46.9%) and 87 
eight ITSs (7.2%), usually relating to anticipated (or feared) negative outcomes of stewardship. These 88 
included concerns about delays in starting antimicrobial treatment or delays in seeing other patients 89 
with urgent needs in the emergency department, and concerns about changes in antimicrobial use 90 
causing acute kidney injury, longer duration of fever, increased duration of mechanical ventilation, 91 
increased allergic reactions, or increased surgical site infections. 92 
 93 
Overall, the review authors concluded that they had found high-certainty evidence that ASI are effective 94 
in increasing compliance with antimicrobial policy and reducing duration of antimicrobial treatment, and 95 
that lower use of antimicrobials likely reduces length of stay and probably does not increase mortality. 96 
Additional trials comparing antimicrobial stewardship with no intervention are unlikely to change these 97 
conclusions. Reflecting the limited range of outcomes examined by the included studies, more research 98 
was recommended to examine the wide range of unintended consequences of restrictive interventions. 99 
 100 
What kinds of consequences should implementers of ASIs consider? 101 
There is no clear consensus on what outcomes should be measured to evaluate the impact of ASI. 102 
Professional organisations have proposed that alongside the process measures of antimicrobial use 103 
which dominate the existing literature, interventions should measure patient outcomes (mortality, 104 
length of hospital stay and readmission rates), and unintended consequences.7-9 In practice, 105 
antimicrobial stewardship trialists and improvers have to make choices about what to measure given 106 
available resources. This paper describes an approach based on quality improvement work in other 107 
contexts to help plan measurement strategies in a structured way to ensure a balanced accounting of 108 
antimicrobial stewardship impact.  109 
 110 
As with other improvement interventions, there are two prominent features of the types of measures 111 
used to evaluate effectiveness in the studies examined. These are whether outcomes are desirable or 112 
undesirable, and whether outcomes are expected or not. Of note is that for some outcomes, desirability 113 
depends on the expected direction of change (an obvious example being that reduced mortality is 114 
desirable, whereas increased mortality is undesirable), but many published papers do not clearly state 115 
their expectations before implementation. Potential metrics can therefore be divided into four main 116 
categories, any of which can be measured in terms of process and outcome, both in the clinical setting 117 
targeted by improvement and other clinical settings in which consequences might occur (for example 118 
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due to readmission to other services). The four type of consequences are adapted from the Diffusion of 119 
Innovations literature10-14 and described in Figure 1: 120 
• ASI goals: the expected and desirable consequences of the improvement intervention.  121 
• ASI trade-offs: the expected but undesirable consequences of the improvement intervention. 122 
Before intervention, these are assumed to be smaller in magnitude than the goals (and so 123 
implicitly are an acceptable compromise), but may include outcomes such as mortality where 124 
any significant increase is likely to outweigh improvement in goals and which are often 125 
measured to reassure about safety.  126 
• ASI pleasant surprises: unexpected and desirable consequences emerging after implementation.  127 
• ASI unpleasant surprises: unexpected and undesirable consequences emerging after 128 
implementation. 129 
 130 
Examples of goals, trade-offs and surprises in the antimicrobial stewardship literature 131 
ASI goals (Expected desirable consequences) 132 
Overall, the primary goal of ASI is to reduce total or specific antimicrobial use. All the interventions 133 
included in the review measured antimicrobial prescribing but only a minority clearly specified other 134 
types of goals such as microbial outcomes. Other pre-specified goals included reduced length of stay 135 
and/or reduced in-hospital mortality in 31 (63%) RCTs but only 6 (5%) ITS studies evaluating stewardship 136 
interventions intended to change antimicrobial prescribing (Table 1).  137 
 138 
ASI trade-offs (Expected undesirable consequences) 139 
Several studies pre-specified increased mortality and increased length of stay as expected undesirable 140 
consequences, with measurement intended to allow examination of trade-offs (length of stay) or 141 
provide reassurance about safety (mortality). For instance, two RCTs15 16 explicitly framed length of stay 142 
and mortality as ‘safety outcomes’ because they were concerned that both might increase although 143 
neither actually did.  Similarly, even in a context where the improvers expected their intervention to 144 
reduce length of stay, they were concerned that this might lead to higher rates of rapid readmission and 145 
measured the latter as a pre-defined trade-off.17 In studies in emergency departments, some authors 146 
were concerned that prioritising rapid antimicrobial administration for patients with fever and 147 
neutropenia might compromise care for other patients. The initial measurement plans therefore 148 
included trade-offs between achieving the goals of more rapid initiation of antimicrobials and potential 149 
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treatment delays for patients with other urgent problems18 19 and/or an expected increase in patients 150 
leaving without being seen.20 In the latter study, other potential trade-offs identified before 151 
implementation included the intervention effect on nurses’ workload when a febrile neutropenic patient 152 
was placed in their nursing area and the potential for staff to develop user fatigue, but the improvers 153 
chose not to explicitly measure these.20 154 
 155 
Pleasant Surprises (Unexpected desirable consequences) 156 
Some consequences are not expected before implementation, and therefore only become visible or 157 
apparent subsequently.  For instance, three RCTs pre-specified length of stay as a trade-off (that is, they 158 
expected or feared an increase due to the stewardship intervention), but actually found unexpected 159 
decreases (a pleasant surprise).21-23 A few studies explicitly examined other outcomes which were 160 
unexpected and desirable, such as an observed reduction in delay to first antimicrobial treatment from 161 
an intervention which aimed to reduce the number of unnecessary diagnostic tests in infants with risk 162 
factors for early-onset neonatal sepsis.24 More commonly, papers speculated that there were 163 
unmeasured pleasant surprises, for example discussion of an intervention to discontinue unnecessary 164 
intravenous antimicrobial therapy suggested that there were ‘unmeasured theoretical benefits’ in terms 165 
of reduced incidence of phlebitis or other potential complications.25 166 
 167 
Unpleasant surprises (Unexpected undesirable consequences) 168 
Only 10 studies In the Cochrane review examined unexpected or surprising negative outcomes. When 169 
outcomes are unexpected, then data have not typically been collected before and after intervention 170 
implementation, and studies most commonly examined unpleasant surprises using case-control, 171 
qualitative and cohort designs. For example, a case-control study investigating an abrupt and persistent 172 
30% increase in the absolute number of reported nosocomial infections found it was actually a pseudo-173 
outbreak caused by physicians altering their threshold for diagnosis and reporting in response to 174 
implementation of a restrictive  antimicrobial policy.26 In response to a similarly restrictive intervention, 175 
qualitative interviews with clinical staff revealed unexpected difficulties with the prior approval process 176 
for restricted antimicrobials, including failure to clearly document approval and ambiguity in the 177 
duration of approval. The consequences were erosion of trust in the accuracy of feedback data about 178 
appropriate use of restricted antimicrobials.27 179 
 180 
7 
 
Four cohort studies investigated post-implementation concerns about restrictive interventions that had 181 
arisen some years after the implementation of ASI (Table 2). The aims of these studies varied 182 
considerably in that one was intended to provide reassurance about the risks of automatic stop orders28 183 
whereas the other three were intended to confirm concerns about prior approval programmes.29-31 As 184 
reported, the results did not reveal any surprises per se because the authors interpreted them as 185 
supporting their predictions that stop orders would be safe and that requiring prior approval carried 186 
risks (Table 2). These conclusions would have been much stronger if the studies had explicitly addressed 187 
the potential trade-offs involved. For example, how much delay in vancomycin treatment in how many 188 
patients would it take to consider modifying a stop order policy?   189 
 190 
Three cohort studies addressed concerns that public reporting of hospital performance on a national 191 
quality indicator of timely treatment of patients with community-acquired pneumonia (CAP) might be 192 
leading to unnecessary antibiotic treatment of patients who did not have pneumonia.32-34 These 193 
concerns were supported by additional studies that were not included in the Cochrane review,35 and the 194 
performance measure was subsequently revised and then withdrawn altogether.36 195 
 196 
One study used an ITS design to address post-implementation concerns that a change in surgical 197 
prophylaxis policy from cefuroxime to flucloxacillin plus gentamicin may have increased risk of 198 
postoperative acute kidney injury (AKI) in orthopaedic patients.37 The results confirmed a clinical 199 
impression of increased AKI, and resulted in a further change to the prophylaxis policy (described in 200 
detail in Table 3 and below). 201 
 202 
Challenges associated with achieving a balanced accounting of ASI impact 203 
The framework described in Figure 1 has the benefit of bringing a systematic approach to considering 204 
the consequences of ASI, which is important because decisions often have to be made in the face of 205 
considerable uncertainty and then adapted to new information. This is illustrated by the experience of 206 
the development, implementation and modification of an ASI intended to reduce the use of surgical 207 
antimicrobial prophylaxis associated with higher risk of CDI in one Scottish Health Board (Table 3).37 AKI 208 
risk was explicitly considered pre-intervention, in response to clinician concern about AKI risks in 209 
changing surgical prophylaxis to gentamicin plus flucloxacillin, and the planned intervention was 210 
amended in the patient group at highest risk of AKI (patients with fractured neck of femur). However, it 211 
was also decided that routine measurement of AKI was not required since the cost outweighed what 212 
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was considered a remote risk in other patients. Post-implementation, further clinical concerns that there 213 
had been increases in AKI in the lower-risk group of patients receiving gentamicin and flucloxacillin 214 
prompted rigorous investigation to quantify whether the perceived risk was real. However, the 215 
Antimicrobial Management Group (AMG) were expecting the analysis to refute the clinical concerns, 216 
and had not considered what to do if the analysis confirmed that there was a problem. When the 217 
analysis showed that gentamicin plus flucloxacillin was causing at least 10 additional cases of AKI per 218 
month in NHS Tayside, there was then a need for rapid decisions to be made with the Health Board 219 
Director of Pharmacy, Medical Director and Chief Executive about how to respond. Decision-making was 220 
complicated by the difficulties of weighing up any potential gain in lower rates of CDI against the 221 
potential harm of higher rates of AKI, but since the number of people developing AKI was approximately 222 
10 times those who might have avoided CDI as a result of the intervention, the surgical prophylaxis 223 
policy was changed to minimise AKI risk. 224 
 225 
Implications for antimicrobial stewardship programmes 226 
Implications for doing and evaluating improvement 227 
Although the focus of this paper is on choice of outcomes, AMTs will also have to ensure that their 228 
evaluation design delivers results that are internally valid in terms of being as resistant to confounding 229 
and bias as possible. Although RCTs remain the ‘gold standard’ for ensuring internal validity, the 230 
Cochrane Effective Practice and Organisation of Care Group also considers trials that allocate non-231 
randomly, controlled before-and-after studies, and ITS studies as allowing reasonable inference of 232 
causality.38 In the field of AMS though, the choice for those with research funding is more likely to be 233 
between cluster-randomised controlled trials (cRCTs) and ITS designs,39 (ideally controlled ITS where 234 
there is a comparison to a setting without an intervention) with ITS designs the most feasible evaluation 235 
design for clinicians and managers seeking to evaluate a local stewardship intervention.40 236 
 237 
Assessing the full value of ASI requires a balanced accounting of the costs, risks and benefits, but 238 
assessment will often be resource constrained meaning that AMTs have to make choices about what to 239 
measure in the face of uncertainty due to the difficulty predicting how a complex, dynamic system will 240 
respond to change.10 41 Before beginning or expanding a stewardship program, the AMT therefore need 241 
to plan their measurement strategy, brainstorming goals and trade-offs, articulate assumptions around 242 
the expected direction of change, and speculate on potential surprises and how they might be revealed. 243 
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The aim should be to identify ASI goals and likely trade-offs, and then to determine which should be 244 
measured. Indeed, many undesirable outcomes are predictable and should be accounted for from the 245 
outset. It should no longer be any surprise to an AMT that stop orders or requirements for prior 246 
approval have the potential to interrupt or delay treatment (Table 2), or that performance 247 
measurement of time to first antibiotic for patients with CAP may lead to unnecessary antibiotic 248 
treatment in patients who do not have pneumonia.35  Consequently, AMTs considering an ASI using 249 
these methods should always consider if measurement of predictable trade-offs is needed,42 although 250 
AMTs still need to carefully identify other likely consequences of their particular ASI in their specific 251 
context.  252 
 253 
Plan do Study Act (PDSA) cycles are a practical method for identifying consequences.43-45 However, the 254 
application of the PDSA methodology to healthcare has often resulted in an over-simplified “Do, Do, Do” 255 
approach focused on desired goals at the expense of study and reflection before and after 256 
implementation, which means that improvement teams often fail to account for unexpected 257 
consequences and may not maximise benefit.46 Two systematic reviews of application of PDSA methods 258 
to healthcare state that they can reveal unanticipated consequences of change but neither actually 259 
includes a detailed consideration of the full range of consequences in their data synthesis framework.45 260 
47 Only one of these reviews included any information about reporting of consequences, finding that 261 
only 6 (6.4%) of 94 included studies reported “disconfirming observations” about the intervention.47 262 
 263 
Furthermore, the Cochrane Review identified that only a small minority of studies explicitly addressed 264 
unintended consequences, and it is notable that four (including the only RCT) were from the same 265 
institution (the University of Pennsylvania School of Medicine).18 28 29 48 These studies were informed by 266 
previous research from the same hospital, which investigated the unintended effects of computerised 267 
physician orders with focus groups, interviews, shadowing and observation of house staff, nurses, 268 
information technology leaders, pharmacy leaders and attending physicians.49 It is likely that this 269 
research increased awareness about unintended consequences of the ASI at this hospital. However, 270 
considering unexpected consequences should be the rule rather than the exception. An ‘improvement 271 
pause’ to take stock at a planned time after implementation will allow teams to consider whether there 272 
is enough evidence that surprises have happened to make it worth systematically measuring their 273 
impact.   274 
 275 
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In this regard, ASPs needs to learn from experience of performance measurement50 and systems 276 
analysis41 in other sectors. Most of the consequences identified by the review arise from one of the 277 
commonest problems with performance measurement: tunnel vision, where what is measured leads to 278 
neglect of unmeasured aspects of performance. However, the Cochrane review also found examples of 279 
misrepresentation of microbiological results,26 30 misinterpretation of information about 280 
appropriateness of prescription of restricted antibiotics,27 and workarounds to avoid prior approval 281 
policies.29 Four strategies have been recommended to minimise the risk of tunnel vision, 282 
misrepresentation and misinterpretation: involving staff at all levels; retaining flexibility in the use of 283 
performance indicators; quantifying every important outcome; and keeping the system under constant 284 
review.50 There are examples of studies in the Cochrane review5 which employed these strategies (Table 285 
4), and they are aligned to the framework in terms of working with stakeholders to identify and measure 286 
a balanced set of processes and outcomes, and ensuring post-implementation review to identify and 287 
measure significant unpleasant surprises.  288 
 289 
Although measurement is central to improvement, qualitative methods have much to offer in the 290 
identification of unexpected consequences to maximise benefit.10 43 44 Qualitative methods can be used 291 
to help design interventions, exemplified by the Reducing Antibiotic Prescribing in Dentistry (RAPiD) 292 
study which used data about community dentists’ perceptions of consequences of using surgical 293 
treatment rather than antimicrobials to design a behavioural change intervention.51 Qualitative methods 294 
can also support post-implementation study and reflection. It is to be expected that clinicians will 295 
sometimes evade restrictive antimicrobial stewardship policies27 in ways which are undermine the 296 
intervention, but the existence, rationale and form of workarounds can also be evidence that clinicians 297 
perceive the restriction to be difficult to safely fit into clinical workflows and that the intervention 298 
therefore needs adaptation.41 43 299 
 300 
Implications for reporting improvement interventions 301 
The Standards for Quality Improvement Reporting Excellence (SQUIRE 2.0) recommend that reporting of 302 
results should include “unintended consequences, such as unexpected benefits, problems, failures or 303 
costs associated with the intervention” (standard 13e).6 However, the detailed explanation and 304 
elaboration document does not specifically mention this or provide an example,52 and the measurement 305 
element (standard 10) focuses on process and outcome measures without specifying that these can 306 
evaluate both positive and negative consequences.6 Similarly, although the Outbreak Reports and 307 
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Intervention studies Of Nosocomial Infection (ORION) guidelines require the reporting of any harms 308 
measured,53 neither the STrengthening the Reporting of OBservational studies in Epidemiology 309 
(STROBE)54 or the proposed antimicrobial stewardship extension (STROBE-AMS) reporting standards55 310 
specifically mention unintended consequences in discussion of outcomes. Irrespective of which 311 
reporting standard is most appropriate to any individual study, we recommend that reports of ASI (and 312 
other improvement interventions) should describe how the initial improvement plan was developed, 313 
including whether and how expected undesirable consequences (trade-offs) were accounted for, 314 
whether there were post-implementation surprises, and whether they were measured. Analysis should 315 
report all measured positive and negative consequences and a balanced interpretation across all 316 
measures.   317 
Conclusion 318 
A large proportion of the ASI reported in the literature only assess impact on their targeted process 319 
goals – antimicrobial prescribing – with limited examination of other potential goals including microbial 320 
and clinical outcomes. Reflecting this and the high certainty that stewardship improves prescribing in 321 
hospitals, the Cochrane review concluded that “future research should instead focus on measuring 322 
clinical outcomes and assessing other measures of patient safety and different stewardship 323 
interventions and explore the barriers and facilitators to implementation” (p31).5 There is however less 324 
certainty about the effects of ASI in the community, although it will be equally important to study a 325 
balanced set of outcomes in that context. 326 
 327 
Achieving a balanced accounting of the impact of an ASI in both hospital and community settings 328 
requires careful consideration of expected undesirable effects (potential trade-offs) from the outset, 329 
and more consideration of unexpected effects after implementation (both pleasant and unpleasant 330 
surprises, although the latter will often be more important). Consensus studies to establish a core 331 
outcome set for studies of antimicrobial stewardship interventions would be useful,56 57 but the 332 
proposed framework supports the systematic consideration of all consequences of improvement before 333 
and after implementation.  334 
335 
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Table 1: Type of outcomes measured in antimicrobial stewardship interventions 536 
Type of outcome measured Randomised control trials (RCT) 
No (%) (n=49) 
Interrupted time series designs (ITS) 
No (%) (n=110b) 
Antimicrobial treatment 46 (93.8) 101 (91.8) 
Surgical antimicrobial prophylaxis 3 (6.1) 9 (8.2) 
Microbial outcomes 5 (10.2) 26 (23.6) 
18 
 
Mortality 28a (57.1) 4c (3.6) 
Length of hospital stay 15a (30.6) 2c (1.8) 
Other outcomesd 23 (46.9) 8 (7.2) 
a. 31 RCTs in total, 16 mortality only, 12 mortality and length of hospital stay, 3 length of stay only 537 
b. 11 ITS studies included a control group for comparison 538 
c. 6 ITS studies in total, no study included both mortality and length of hospital stay 539 
d. Most commonly measured other outcomes included delays in starting antimicrobial treatment, 540 
duration of fever, time spent on mechanical ventilation or increased allergic reactions 541 
 542 
 543 
 544 
 545 
 546 
 547 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
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Table 2: Cohort studies of unintended consequences of restrictive interventions 
Study Restrictive intervention Source of concern  Measures and results Author conclusions 
Connor 
200728 
Automatic stop order 
for vancomycin after 
72h treatment.58 
Stop orders may lead to 
inadvertent discontinuation 
or interruption of 
appropriate therapy. 
Interruption of vancomycin:  
1. Frequency 8% 
2. Duration 6-36 hours 
“Automatic stop orders are unlikely to 
pose a substantial risk of denying 
necessary antibiotic therapy to patients. 
These data should provide reassurance to 
Antimicrobial Stewardshipi Programmes 
(ASPs) that are considering instituting 
automatic stop orders.” 
La Rosa 
200729 
A prior approval ASP 
that was active 
between 8am and 
11pm.58 
In a prior qualitative study 
at the same hospital some 
house staff stated that they 
engaged in “stealth dosing” 
(waiting until after the prior-
approval period ended to 
prescribe restricted 
antimicrobial drugs).49  
1. Prescribing of restricted 
antibiotics was 57% of total 
11-12pm vs 50% 10-11pm 
2. Restricted therapy 
continued for >1 day 65% 
after 11pm vs 89% before 
11pm. 
“Although ASPs have been shown to be 
beneficial, our findings reflect a potential 
limitation of these programes. Further 
efforts to identify and correct the 
limitations of existing ASPs are needed to 
optimise their usefulness.” 
Linkin 
200730 
A prior approval ASP 
that was active 
between 8am and 
11pm.58 
 
Data communicated from 
clinicians were found to 
contain inaccurate patient 
information in over 40% of 
calls made to practitioners 
in a prior study of this 
hospital’s ASP.48 
Inappropriate antimicrobial 
therapy* with inaccurate data vs 
other calls: 
1. Any data inaccurate:  
OR 2.2, CI 1.1-4.6 
2. Microbiological data 
inaccurate:  
OR 7.5, CI 2.1-27.0 
“Studies are needed to test and extend 
our findings by evaluating other causes of 
inappropriate recommendations, 
downstream clinical outcomes, and the 
effect of technological interventions.”  
“Clinicians and ASP practitioners should 
confirm critical communicated data 
before use in prescribing decisions.” 
Winters 
201031 
A prior approval ASP. 
Stat doses of restricted 
antimicrobials could be 
ordered without 
approval 10pm to 8am 
but not during the day. 
Year of introduction of 
ASP not clear 
Prior approval may delay 
time to first antibiotic dose 
Delays when the antimicrobial 
was restricted vs not restricted: 
1. One hour 
a. 8am-10pm: 46% vs 36% 
b. 10pm-8am: 39% vs 36% 
2. Two hours or more 
a.  8am-10pm: 24% vs 16% 
b. 10pm-8am: 15% vs 14% 
“Delays in antimicrobial administration 
should be kept to a minimum and avoided 
altogether in critically ill patients. One 
way to accomplish this might be to not 
require approval for the first 
administration of a stat antibiotic but 
require approval of subsequent doses.” 
*Most common reason for rating a recommendation as inappropriate was that antimicrobial therapy was not indicated. 
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Table 3: Potential challenges in achieving a balanced accounting of intervention impact: Changing 
policies for surgical prophylaxis in one Scottish Health Board 
 
In response to high rates of Clostridium difficile infection (CDI), the Antibiotic Management Group in the 
855 bedded Ninewells Hospital in NHS Tayside introduced a number of measures intended to reduce the 
use of antibiotics associated with a high risk of CDI in analysis of local data.59 Antimicrobial prophylaxis 
for orthopaedic implant surgery was changed from single dose cefuroxime 1.5g to four doses of 
flucloxacillin 1g plus single dose gentamicin 4mg/kg. During intervention planning, concerns were raised 
about the renal risks of the new regimen in patients with fractured neck of femur who are older and 
have higher prevalence of chronic kidney disease, resulting in the recommendation use of co-amoxiclav 
(which although still relatively high risk for CDI remained on the formulary for some indications, whereas 
cefuroxime did not). There was no plan to measure rates of acute kidney injury (AKI) in either group of 
orthopaedic patients because AKI risks from the chosen single dose prophylaxis in each group were 
considered remote (i.e. a trade-off was not considered likely). 
 
 In 2012, another Scottish hospital reported concerns about increased rates of postoperative AKI in 
orthopaedic patients from the same change in surgical prophylaxis.60 In response to this concern, NHS 
Tayside carried out an interrupted time series analysis with the belief that it would refute the concern. 
The analysis unexpectedly confirmed increased rates of AKI in orthopaedic surgery but not in other 
types of surgery (a very unpleasant surprise),37 with a subsequent reduction in AKI when antimicrobial 
prophylaxis was changed to co-amoxiclav for all types of orthopaedic surgery.61 
 
More detailed analysis has shown that AKI rates did not change after the first change in policy in 2008 
for people with fractured neck of femur (who had a switch from cefuroxime to co-amoxiclav; pre-
intervention 15.0% vs post-intervention 14.8%) although CDI rates in this group more than halved (3.6% 
vs 1.7%). For other implant surgery where prophylaxis changed from cefuroxime to flucloxacillin/ 
gentamicin, AKI rates pre- and post-intervention were 6.2% and 10.8%, and C diff rates 0.8% vs 0.4%) 
confirming that any possible benefit in terms of reduced CDI in this group was likely to be much smaller 
than the increased potential harm in terms of AKI. 
 
21 
 
Table 4: Strategies for minimising the unintended consequences of performance measurement50 and 
examples of studies from the Cochrane review5 
Strategy Examples from the Cochrane review 
Involve staff at all levels Forming inter-professional improvement teams with front line staff 
involving senior and junior doctors, nurses and pharmacists.20 62  
Involving management at clinical service and hospital levels.20 62  
Involving junior doctors63 and other front line staff19 20 such as 
pharmacists in interpreting and learning from collected data. 
Retain flexibility in the use of 
performance indicators 
Using process maps to identify performance indicators and tests of 
change to modify them.20 62  
Using run charts to identify outliers and chart review to investigate 
causes and targets for change.20 
Using staff coaching to identify factors contributing to performance 
lapses and invite suggestions for improvement.19 
Quantify every important 
outcome 
Two studies identified delay in treatment of other patients as a potential 
consequence of reducing time to first antibiotic dose for children with 
sepsis in Emergency Departments.19 20 However, only one went on to test 
and implement quantitative measures of identified trade-offs (time left 
without being seen for all patients in the emergency department and 
time to first dose of beta-agonist for children with asthma).20 
Keep system under constant 
review 
Specifying two or more intervention periods to allow review of 
consequences and adaptation of intervention.19 20 62 
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Figure 1- Types of consequences of antimicrobial stewardship interventions  
 
 
 
 
